Abstract
Analysis of the mitochondrial proteome would provide valuable insight into the function of this important organelle, which plays key roles in energy metabolism, apoptosis, free radical production, thermogenesis, and calcium signaling. It could also increase our understanding about the mechanisms that promote mitochondrial disease. To identify proteins that are antigenically dominant in human liver mitochondria, we generated >240 hybridoma cell lines from native mitochondrial proteins after cell fusion, screening, and cloning. Antibodies that recognized mitochondrial proteins were identified by screening human liver cDNA expression libraries. In this study, we identified 6 major antigens that were recognized by at least 2 different monoclonal antibodies (mAbs). The proteins that were antigenically dominant were: acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase), aldehyde dehydrogenase 1 family member A1, carbamoyl phosphate synthetase 1, dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex), enoyl coenzyme A hydratase 1, and hydroxysteroid (11-beta) dehydrogenase 1. We also determined the subcellular localizations of these enzymes within the mitochondria using immunohistocytochemistry. We believe that these well-characterized antibodies will provide a valuable resource for the Human Liver Proteome Project (HLPP), and will make studies aimed at investigating liver mitochondrial function far easier to perform in future. Our results provide strong evidence that, (i) depletion of dominant proteins from liver mitochondrial samples is possible and, (ii) the approaches adopted in this study can be used to explore or validate protein-protein interactions in this important organelle.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Darley-Usmar V M, Rickwood D, Wilson M T. Mitochondria: a Practical Approach. Oxford: IRL Press, 1987
Cordwell S J, Wilkins M R, Cerpa-Poljak A, et al. Cross-species identification of proteins separated by two-dimensional gel electrophoresis using matrix-assisted laser desorption ionisation/time-of-flight mass spectrometry and amino acid composition. Electrophoresis, 1995, 16: 438–443, 1:CAS:528:DyaK2MXkvFWhtbg%3D, 10.1002/elps.1150160171, 7607178
Taylor S W, Fahy D, Zhang B, et al. Characterization of the human heart mitochondrial proteome. Nat Biotechnol, 2003, 21: 281–286, 1:CAS:528:DC%2BD3sXhsFajs7k%3D, 10.1038/nbt793, 12592411
Kusnezow W, Hoheisel J D. Antibody microarrays: promises and problems. Biotechniques, 2002, Suppl: 14–23
Lemasters J J, Qian T, Bradham C A, et al. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death. J Bio energ Biomembr, 1999, 31: 305–319, 1:CAS:528:DC%2BD3cXotF2rtw%3D%3D, 10.1023/A:1005419617371
Beal M F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci, 2000, 23: 298–304, 1:CAS:528:DC%2BD3cXktlCnu7g%3D, 10.1016/S0166-2236(00)01584-8, 10856939
Chinnery P F, Howell N, Andrews R M, et al. Mitochondrial DNA analysis: polymorphisms and pathogenicity. J Med Genet, 1999, 36: 505–510, 1:CAS:528:DyaK1MXms12gtbc%3D, 10424809
Parrella P, Xiao Y, Fliss M, et al. Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res, 2001, 61: 7623–7626, 1:CAS:528:DC%2BD3MXnvFShtrg%3D, 11606403
Hibi K, Nakayama H, Yamazaki T, et al. Mitochondrial DNA alteration in esophageal cancer. Int J Cancer, 2001, 92: 319–321, 1:CAS:528:DC%2BD3MXjtVWitLg%3D, 10.1002/ijc.1204, 11291064
Simonnet H, Alazard N, Pfeiffer K, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis, 2002, 23: 759–768, 1:CAS:528:DC%2BD38XktFyqsLw%3D, 10.1093/carcin/23.5.759, 12016148
Copeland W C, Wachsman J T, Johnson F M, et al. Mitochondrial DNA alterations in cancer. Cancer Invest, 2002, 20: 557–569, 1:CAS:528:DC%2BD38Xls1eit7c%3D, 10.1081/CNV-120002155, 12094550
Modica-Napolitano J S, Singh K K. Mitochondrial dysfunction in cancer. Mitochondron, 2004, 4: 755–762, 1:CAS:528:DC%2BD2cXhtVCgsL7P, 10.1016/j.mito.2004.07.027
Leonard J V, Schapira A H. Mitochondrial respiratory chain disorders II: eurodegenerative disorders and nuclear gene defects. Lancet, 2000, 355: 389–394, 1:CAS:528:DC%2BD3cXitVaqsLs%3D, 10.1016/S0140-6736(99)05226-5, 10665569
Leonard J V, Schapira A H. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet, 2000, 355: 299–304, 1:STN:280:DC%2BD3c7jslGmsw%3D%3D, 10.1016/S0140-6736(99)05225-3, 10675086
DiMauro S, Bonilla E, Davidson M, et al. Mitochondria in neuromuscular disorders. Biochim Biophys Acta, 1998, 1366: 199–210, 1:CAS:528:DyaK1cXltFWksb8%3D, 10.1016/S0005-2728(98)00113-3, 9714805
Zeviani M, Spinazzola A, Carelli V. Nuclear genes in mitochondrial disorders. Curr Opin Genet Dev, 2003, 13: 262–270, 1:CAS:528:DC%2BD3sXkt1KgtbY%3D, 10.1016/S0959-437X(03)00052-2, 12787788
Mizuno Y, Ohta S, Tanaka M, et al. Deficiencies in Complex I subunits of the respiratory chain in Parkinson’s disease. Biochem Biophys Res Commun, 1989, 163: 1450–1455, 1:CAS:528:DyaL1MXmtFarsLg%3D, 10.1016/0006-291X(89)91141-8, 2551290
Schapira A H, Cooper J M, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990, 54: 823–827, 1:CAS:528:DyaK3cXhsFKiur4%3D, 10.1111/j.1471-4159.1990.tb02325.x, 2154550
Betarbet R, Sherer T B, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci, 2000, 3: 1301–1306, 1:CAS:528:DC%2BD3cXosVGgsbg%3D, 10.1038/81834, 11100151
Kim S H, Vlkolinsky R, Cairns N, et al. The reduction of NADH: Ubiquinone oxidoreductase 24- and 75-kD subunits in brains of patients with Down syndrome and Alzheimer’s disease. Life Sci, 2001, 68: 2741–2750, 1:CAS:528:DC%2BD3MXjs1ajs7k%3D, 10.1016/S0024-3205(01)01074-8, 11400916
Arenas J, Campos Y, Ribacoba R, et al. Complex I defect in muscle from patients with Huntington’s disease. Ann Neurol, 1998, 43: 397–400, 1:STN:280:DyaK1c7msFertw%3D%3D, 10.1002/ana.410430321, 9506560
Vielhaber S, Kunz D, Winkler K, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain, 2000, 123: 1339–1348, 10.1093/brain/123.7.1339, 10869047
Vielhaber S, Schroder R, Winkler K, et al. Defective mitochondrial oxidative phosphorylation in myopathies with tubular aggregates originating from sarcoplasmic reticulum. J Neuropathol Exp Neurol, 2001, 60: 1032–1040, 1:CAS:528:DC%2BD3MXosFChu7w%3D, 11706933
Dror N, Klein E, Karry R, et al. State-dependent alterations in mitochondrial complex I activity in platelets: A potential peripheral marker for schizophrenia. Mol Psychiatry, 2002, 7: 995–1001, 1:CAS:528:DC%2BD38XotFWrsrc%3D, 10.1038/sj.mp.4001116, 12399953
Lenaz G, D’Aurelio M, Merlo Pich M, et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta, 2000, 1459: 397–404, 1:CAS:528:DC%2BD3cXlslWruro%3D, 10.1016/S0005-2728(00)00177-8, 11004456
Ling Y H, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol, 2008, 74: 793–806, 1:CAS:528:DC%2BD1cXhtVClt7nF, 10.1124/mol.107.044396, 18524889
Murray J, Zhang B, Taylor S W, et al. The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification. J Bio Chem, 2003, 278: 13619–13622, 1:CAS:528:DC%2BD3sXjtVSisb0%3D, 10.1074/jbc.C300064200
Sercarz E E, Lehmann P V, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol, 1993, 11: 729–766, 1:CAS:528:DyaK3sXkt1Kjtr8%3D, 10.1146/annurev.iy.11.040193.003501, 7682817
Wienhold W, Malcherek G, Jung C, et al. An example of immunodominance: engagement of synonymous TCR by invariant CDR3β. Int Immunol, 2000, 12: 747–756, 1:CAS:528:DC%2BD3cXks1ylsrg%3D, 10.1093/intimm/12.6.747, 10837402
Gao J, Gao Y, Ju Y, et al. Proteomics-based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins. Proteomics, 2006, 6: 427–437, 1:CAS:528:DC%2BD28Xhs1ehtrc%3D, 10.1002/pmic.200500409, 16342244
Mootha V K, Bunkenborg J, Olsen J V, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell, 2003, 115: 629–640, 1:CAS:528:DC%2BD3sXps1OhtLk%3D, 10.1016/S0092-8674(03)00926-7, 14651853
Lusty C J. Carbamoylphosphate synthetase I of rat liver mitochondria: Purification, properties, and polypeptide molecular weight. Eur J Biochem, 1978, 85: 373–383, 1:CAS:528:DyaE1cXktFyqtb8%3D, 10.1111/j.1432-1033.1978.tb12249.x, 206435
Raymond Y, Shore G C. Biogenesis of the mitochondrial enzyme, carbamyl phosphate synthetase: Appearance during fetal development of rat liver and rapid repression in freshly dispersed hepatocytes. Biochim Biophys Acta, 1981, 656: 111–119, 1:CAS:528:DyaL38XktlSk, 7306548
Saarelainen S, Zeiler T, Rautiainen J, et al. Lipocalin allergen Bos d 2 is a weak immunogen. Int Immunol, 2002, 14: 401–409, 1:CAS:528:DC%2BD38Xis1Knt7o%3D, 10.1093/intimm/14.4.401, 11934876
Nagata N, Matsuda I, Qyanagi K. Estimated frequency of urea cycle enzymopathies in Japan. Am J Med Genet, 1991, 39: 228–229, 1:STN:280:DyaK3M3ptVWgsA%3D%3D, 10.1002/ajmg.1320390226, 2063931
Cardona D M, Zhang X, Liu C. Loss of carbamoyl phosphate synthetase I in small-intestinal adenocarcinoma. Am J Clin Pathol, 2009, 132: 877–882, 1:CAS:528:DC%2BD1MXhs1Slt7vJ, 10.1309/AJCP74XGRFWTFLJU, 19926579
Head R A, Brown R M, Zolkipli Z, et al. Clinical and genetic spectrum of pyruvate dehydrogenase deficiency: Dihydrolipoamide acetyltransferase (E2) deficiency. Ann Neurol, 2005, 58: 234–241, 1:CAS:528:DC%2BD2MXps1Cgurk%3D, 10.1002/ana.20550, 16049940
Haselbeck R J, Hoffmann I, Duester G. Distinct functions for Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid signaling pathways. Dev Genet, 1999, 25: 353–364, 1:CAS:528:DC%2BD3cXhtlKjsQ%3D%3D, 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G, 10570467
Molotkov A, Duester G. Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid. J Biol Chem, 2003, 278: 36085–36090, 1:CAS:528:DC%2BD3sXnt1aqurs%3D, 10.1074/jbc.M303709200, 12851412
Moreb J S, Baker H V, Chang L J, et al. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer, 2008, 7: 87, 10.1186/1476-4598-7-87, 19025616
Levi B P, Yilmaz O H, Duester G, et al. Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems. Blood, 2009, 113: 1670–1680, 1:CAS:528:DC%2BD1MXisV2iurc%3D, 10.1182/blood-2008-05-156752, 18971422
Moreb J S, Mohuczy D, Ostmark B, et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmaco, 2007, 59: 127–136, 1:CAS:528:DC%2BD28Xht1entL%2FO, 10.1007/s00280-006-0233-6
Ekhart C, Rodenhuis S, Smits P H, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genom, 2008, 18: 1009–1015, 1:CAS:528:DC%2BD1cXht1Cru7fJ, 10.1097/FPC.0b013e328313aaa4
Jackson S, Kler R S, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest, 1992, 90: 1219–1225, 1:STN:280:DyaK3s%2Fhs1ynug%3D%3D, 10.1172/JCI115983, 1401059
Cao W, Liu N, Tang S, et al. Acetyl-Coenzyme A acyltransferase 2 attenuates the apoptotic effects of BNIP3 in two human cell lines. Biochim Biophys Acta, 2008, 1780: 873–880, 1:CAS:528:DC%2BD1cXmtVSjurY%3D, 18371312
Vallat L, Magdelénat H, Merle-Béral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood, 2003, 101: 4598–4606, 1:CAS:528:DC%2BD3sXktFKgsrw%3D, 10.1182/blood-2002-06-1743, 12586635
Stegk J P, Ebert B, Martin H J, et al. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. Mol Cell Endocrinol, 2009, 301: 104–108, 1:CAS:528:DC%2BD1MXit1Ohu7o%3D, 10.1016/j.mce.2008.10.030, 19022342
Hale C, Wang M. Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes. Mini Rev Med Chem, 2008, 8: 702–710, 1:CAS:528:DC%2BD1cXnslWkuro%3D, 10.2174/138955708784567421, 18537725
Hwang J Y, Lee S H, Kim G S, et al. HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone, 2009, 45: 1098–1103, 1:CAS:528:DC%2BD1MXhtlGit7fO, 10.1016/j.bone.2009.07.080, 19651257
Tashjian R Z, Lin C, Aswad B, et al. 11beta-hydroxysteroid dehydrogenase type 1 expression in periprosthetic osteolysis. Orthopedics, 2008, 31: 545, 10.3928/01477447-20080601-32, 19292355
Ahmed A, Saksena S, Sherlock M, et al. Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf), 2008, 68: 898–903, 1:CAS:528:DC%2BD1cXnvFentrc%3D, 10.1111/j.1365-2265.2007.03125.x
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Ju, Y., Yang, J., Liu, R. et al. Antigenically dominant proteins within the human liver mitochondrial proteome identified by monoclonal antibodies. Sci. China Life Sci. 54, 16–24 (2011). https://doi.org/10.1007/s11427-010-4115-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-010-4115-0